Physician profile
James M Ulery
NPI 1043313919
$22,529.39
in general payments reported to CMS, 2019-2025
37 companies · $1,965 in 2025
The $1,965 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,777 · 2020: $9,900 · 2021: $3,672 · 2022: $984 · 2023: $1,870 · 2024: $2,361 · 2025: $1,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,829 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,829.13 |
| Education | $366.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $9,777.91 | 2020-2021 | |
| Janssen Biotech, INC. | $2,041.35 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $1,749.69 | 2019-2025 | Rinvoq, Skyrizi |
| Almirall LLC | $1,025.39 | 2021-2024 | Klisyri |
| Novartis Pharmaceuticals Corporation | $861.82 | 2019-2025 | |
| Ucb, INC. | $780.34 | 2019-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $693.39 | 2022-2023 | Sotyktu |
| Dermavant Sciences, INC. | $664.39 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $582.16 | 2019-2025 | |
| Amgen INC. | $579.85 | 2019-2024 | Otezla, Enbrel |
| Pfizer INC. | $509.85 | 2019-2023 | |
| Galderma Laboratories, L.P. | $444.15 | 2019-2025 | Nemluvio, Oracea |
| Lilly USA, LLC | $405.08 | 2019-2025 | Taltz, Ebglyss, Zepbound |
| Genzyme Corporation | $356.18 | 2019-2025 | |
| Journey Medical Corporation | $290.92 | 2023-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $229.53 | 2019-2023 | |
| Organon LLC | $225.20 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $220.73 | 2023-2024 | Zoryve |
| Leo Pharma INC. | $205.69 | 2019-2025 | Adbry |
| Verrica Pharmaceuticals INC. | $185.41 | 2024-2025 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $160.87 | 2019-2020 | |
| Dermira, INC. | $95.60 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $75.27 | 2019-2022 | |
| Medimetriks Pharmaceuticals, INC. | $66.93 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $50.00 | 2019-2021 | |
| Incyte Corporation | $49.44 | 2022-2024 | Opzelura |
| Janssen Scientific Affairs, LLC | $35.51 | 2019 | |
| Celgene Corporation | $30.84 | 2019 | |
| Botanix Sb INC | $24.90 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $24.43 | 2025 | Xtrac |
| Aclaris Therapeutics, INC. | $22.80 | 2019 | |
| Organogenesis INC. | $18.30 | 2023 | Puraply |
| Genentech USA, INC. | $17.39 | 2019 | |
| Sebela Pharmaceuticals INC. | $13.60 | 2019 | |
| Biofrontera INC. | $11.99 | 2020 | |
| Prugen, INC. Pharmaceuticals | $2.49 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ulery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.